Home LiteratureArticle Details
PMID: 17144914 Published · epublish English Journal Article Research Support, N.I.H., Intramural

Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.

Retrovirology ·Vol. 3 ·2006-12-04 ·Pages 90

Gallo SA, Reeves JD, Garg H, Foley B, Doms RW, Blumenthal R

Abstract

HIV envelope glycoprotein (Env)-mediated fusion is driven by the concerted coalescence of the HIV gp41 N-helical and C-helical regions, which results in the formation of 6 helix bundles. Kinetics of HIV Env-mediated fusion is an important determinant of sensitivity to entry inhibitors and antibodies. However, the parameters that govern the HIV Env fusion cascade have yet to be fully elucidated. We address this issue by comparing the kinetics HIV-1IIIB Env with those mediated by HIV-2 from two strains with different affinities for CD4 and CXCR4. HIV-1 and HIV-2 Env-mediated cell fusion occurred with half times of about 60 and 30 min, respectively. Binding experiments of soluble HIV gp120 proteins to CD4 and co-receptor did not correlate with the differences in kinetics of fusion mediated by the three different HIV Envs. However, escape from inhibition by reagents that block gp120-CD4 binding, CD4-induced CXCR4 binding and 6-helix bundle formation, respectively, indicated large difference between HIV-1 and HIV-2 envelope glycoproteins in their CD4-induced rates of engagement with CXCR4. The HIV-2 Env proteins studied here exhibited a significantly reduced window of time between the engagement of gp120 with CD4 and exposure of the CXCR4 binding site on gp120 as compared with HIV-1IIIB Env. The efficiency with which HIV-2 Env undergoes this CD4-induced conformational change is the major cause of the relatively rapid rate of HIV-2 Env mediated-fusion.

MeSH Terms
CD4 Antigens/metabolism Cell Line HIV Envelope Protein gp120/metabolism HIV Fusion Inhibitors/pharmacology HIV-1/metabolism,pathogenicity HIV-2/metabolism,pathogenicity HeLa Cells Humans Kinetics Membrane Fusion Receptors, CXCR4/metabolism
Chemicals
CD4 Antigens HIV Envelope Protein gp120 HIV Fusion Inhibitors Receptors, CXCR4
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Gallo Stephen A
Center for Cancer Research Nanobiology Program, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, USA. sgallo@aibs.org
Reeves Jacqueline D
Garg Himanshu
Foley Brian
Doms Robert W
Blumenthal Robert
References (43)
43 references, click to expand
  1. HIV-1 entry inhibitors in the side pocket.
    Cell. 1999 Oct 29;99(3):243-6 PMID: 10555140
  2. Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.
    J Virol. 2005 Oct;79(19):12231-41 PMID: 16160149
  3. AIDS as a zoonosis: scientific and public health implications.
    Science. 2000 Jan 28;287(5453):607-14 PMID: 10649986
  4. Varying effects of temperature, Ca(2+) and cytochalasin on fusion activity mediated by human immunodeficiency virus type 1 and type 2 glycoproteins.
    FEBS Lett. 2000 Jun 2;474(2-3):246-51 PMID: 10838094
  5. Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles.
    J Virol. 2000 Oct;74(20):9381-7 PMID: 11000206
  6. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.
    J Cell Biol. 2000 Oct 16;151(2):413-23 PMID: 11038187
  7. HIV-1 membrane fusion: targets of opportunity.
    J Cell Biol. 2000 Oct 16;151(2):F9-14 PMID: 11038194
  8. Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.
    Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12794-9 PMID: 11050186
  9. The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter].
    J Virol. 2001 Mar;75(6):2982-92 PMID: 11222723
  10. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process.
    Biochemistry. 2001 Oct 16;40(41):12231-6 PMID: 11591141
  11. Envelope glycoprotein cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab acceptor.
    J Virol. 2002 Jan;76(1):327-37 PMID: 11739697
  12. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
    J Virol. 2002 Mar;76(6):2683-91 PMID: 11861835
  13. Leucine zipper domain of HIV-1 gp41 interacted specifically with alpha-catenin.
    Biochem Biophys Res Commun. 2002 Mar 15;291(5):1239-44 PMID: 11883950
  14. Human immunodeficiency virus type 2.
    J Gen Virol. 2002 Jun;83(Pt 6):1253-65 PMID: 12029140
  15. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54 PMID: 12444251
  16. Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins.
    J Virol. 2003 Jan;77(2):931-42 PMID: 12502809
  17. Membrane fusion.
    Chem Rev. 2003 Jan;103(1):53-69 PMID: 12517181
  18. The HIV Env-mediated fusion reaction.
    Biochim Biophys Acta. 2003 Jul 11;1614(1):36-50 PMID: 12873764
  19. Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity.
    J Virol. 2004 Jan;78(2):1026-31 PMID: 14694135
  20. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail.
    J Virol. 2004 Apr;78(7):3429-35 PMID: 15016865
  21. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.
    J Virol. 2004 May;78(10):5476-85 PMID: 15113926
  22. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    J Mol Biol. 2004 Jun 25;340(1):9-14 PMID: 15184018
  23. Epitopes of the CD4 antigen and HIV infection.
    Science. 1986 Nov 28;234(4780):1120-3 PMID: 2430333
  24. Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus.
    Virology. 1990 Sep;178(1):134-42 PMID: 2117828
  25. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.
    J Virol. 1991 Jan;65(1):31-41 PMID: 1985202
  26. Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex.
    Virology. 1992 Mar;187(1):233-41 PMID: 1736526
  27. Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein.
    Virology. 1993 Sep;196(1):89-100 PMID: 8356808
  28. Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein.
    J Virol. 1995 Aug;69(8):5199-202 PMID: 7609094
  29. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.
    J Virol. 1996 Jan;70(1):341-51 PMID: 8523546
  30. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.
    J Virol. 1997 Feb;71(2):1453-65 PMID: 8995671
  31. A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers.
    Biochemistry. 1997 Apr 29;36(17):5157-69 PMID: 9136877
  32. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
    J Exp Med. 1997 Oct 20;186(8):1383-8 PMID: 9334378
  33. A synthetic peptide corresponding to the carboxy terminus of human immunodeficiency virus type 1 transmembrane glycoprotein induces alterations in the ionic permeability of Xenopus laevis oocytes.
    AIDS Res Hum Retroviruses. 1997 Nov 20;13(17):1525-32 PMID: 9390752
  34. Human erythrocyte glycolipids promote HIV-1 envelope glycoprotein-mediated fusion of CD4+ cells.
    Biochem Biophys Res Commun. 1998 Jan 6;242(1):219-25 PMID: 9439639
  35. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41.
    J Cell Biol. 1998 Jan 26;140(2):315-23 PMID: 9442107
  36. Capture of an early fusion-active conformation of HIV-1 gp41.
    Nat Struct Biol. 1998 Apr;5(4):276-9 PMID: 9546217
  37. HIV entry and its inhibition.
    Cell. 1998 May 29;93(5):681-4 PMID: 9630213
  38. Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains.
    J Virol. 1999 May;73(5):4062-73 PMID: 10196302
  39. Structural basis for membrane fusion by enveloped viruses.
    Mol Membr Biol. 1999 Jan-Mar;16(1):3-9 PMID: 10332732
  40. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.
    Proc Natl Acad Sci U S A. 1999 May 25;96(11):6359-64 PMID: 10339592
  41. The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.
    J Virol. 2005 Jan;79(1):106-15 PMID: 15596806
  42. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    J Med Chem. 2005 Apr 21;48(8):3036-44 PMID: 15828842
  43. Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF.
    Curr Biol. 1999 Nov 4;9(21):1271-4 PMID: 10556093
Article Info
Journal
Retrovirology
Abbr.
Retrovirology
ISSN
1742-4690
Published
2006-12-04
Epub
2006-00-04
Pages
90
Language
English
Region
England
NLM ID
101216893
PMCID
PMC1693918
Subset
IM
Grants
NIMHD NIH HHS · L60 MD003100 · United States
Intramural NIH HHS · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com